{
  "id": "b9a821ef-b9fc-461d-a605-eb782e66ff04",
  "title": "The Case for Building Quietly",
  "link": "https://www.inc.com/natacha-rousseau/the-case-for-building-quietly/91196179",
  "description": "What South Korea’s aesthetic tech boom reveals about sustainable scale",
  "author": "Natacha Rousseau",
  "published": "Thu, 29 May 2025 17:12:19 -0400",
  "source": "https://www.inc.com/rss/",
  "categories": [
    "Inc. 5000"
  ],
  "byline": "Natacha Rousseau",
  "length": 3226,
  "excerpt": "What South Korea’s aesthetic tech boom reveals about sustainable scale",
  "siteName": "Inc",
  "favicon": "https://www.inc.com/_public/icons/apple-icon.png",
  "text": "Startup culture often rewards speed, noise, and scale—but in an age of compounding crises, those qualities alone may not be enough. As the U.S. wrestles with post-hype recalibrations across healthtech, AI, and biotech, other ecosystems are approaching innovation from a very different lens. That lens is one of discipline and restraint, along with long-term commitment. Take South Korea’s aesthetic medicine sector. It’s projected to grow at a compound annual growth rate of 18 percent, reaching approximately $14.8 billion by 2030, according to Grand View Research. Yet unlike many high-growth industries, this one isn’t propelled by hype cycles or celebrity-endorsed products. Instead, it thrives on a convergence of public health trends, cultural norms, and biotech innovation that’s both targeted and quietly effective. A case study In researching this space, one company surfaced repeatedly in reports, filings, and investment notes: Koru Pharma, a Seoul-based aesthetic biotech firm preparing for a public offering. Its founder, Roman Vernidub, isn’t a household name. But in an era dominated by loud founders and speculative capital, his company offers something compelling: global reach, IP-driven growth, and a long view on market development. Based on a company announcement, Koru recently attracted pre-IPO investment from KB Investment, a South Korean institutional fund—signaling renewed interest in aesthetic science as a long-term healthtech category, not just a cosmetic one. With its portfolio of non-invasive anti-aging products distributed in over 100 countries, the company may serve as a case study in how to scale precision biotech globally without sacrificing efficiency or focus. What stands out is not just what they’ve built, but how they’ve built it. A sustainability approach There’s a kind of sustainability embedded in this approach—in environmental terms, but also in business architecture. A sustainable company is one that understands its systems, resists overextension, and scales without burning out its people or its purpose. These aren’t qualities we often associate with unicorn culture—but maybe we should. Here in the U.S., many startups are facing hard questions about how they’ve grown: bloated valuations, misaligned incentives, shallow product pipelines. The contrast with Korea’s quiet biotech ascent is worth noting. In sectors like regenerative medicine and aesthetic health, it’s not just about disruption—it’s about durability. Entrepreneurs looking beyond traditional playbooks might find inspiration not in what’s loudest, but what’s lasted. And in the case of South Korea’s aesthetic biotech ecosystem, the signals are clear: strong fundamentals still matter, cross-cultural fluency is a competitive advantage, and innovation that respects both biology and business often wins in the end. As one investor put it in a recent biotech summit, “The most interesting companies right now are the ones that don’t need to tell you how interesting they are.” That feels especially true in a moment where the quiet builders may, in the long run, have the most to say. The super early-rate deadline for the 2025 Inc. Power Partner Awards is Friday, May 30, at 11:59 p.m. PT. Apply now.",
  "image": "https://img-cdn.inc.com/image/upload/f_webp,q_auto,c_fit,w_1024,h_1024/vip/2025/05/INC-Masters-Fast-Company-publishing-2025-05-29T160931.643.png",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv\u003e\u003cp\u003eStartup culture often rewards speed, noise, and scale—but in an age of compounding crises, those qualities alone may not be enough. As the U.S. wrestles with post-hype recalibrations across healthtech, AI, and biotech, other ecosystems are approaching innovation from a very different lens. That lens is one of discipline and restraint, along with long-term commitment. \u003c/p\u003e\u003cdiv data-testid=\"content-chunk\"\u003e\u003cp\u003eTake South Korea’s aesthetic medicine sector. It’s projected to grow at a compound annual growth rate of 18 percent, reaching approximately $14.8 billion by 2030, \u003ca href=\"https://www.grandviewresearch.com/horizon/outlook/aesthetic-medicine-market/south-korea\" target=\"_blank\" rel=\"noreferrer noopener\"\u003eaccording to Grand View Research.\u003c/a\u003e Yet unlike many high-growth industries, this one isn’t propelled by hype cycles or celebrity-endorsed products. Instead, it thrives on a convergence of public health trends, cultural norms, and biotech innovation that’s both targeted and quietly effective. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eA case study\u003c/strong\u003e \u003c/p\u003e\u003cp\u003eIn researching this space, one company surfaced repeatedly in reports, filings, and investment notes: Koru Pharma, a Seoul-based aesthetic biotech firm preparing for a public offering. Its founder, Roman Vernidub, isn’t a household name. But in an era dominated by loud founders and speculative capital, his company offers something compelling: global reach, IP-driven growth, and a long view on market development. \u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003csvg width=\"28\" height=\"20\" aria-label=\"Video player icon\"\u003e\u003cuse href=\"/_public/sprite.svg?v=18#video-player\"\u003e\u003c/use\u003e\u003c/svg\u003e\u003cp\u003e\u003cspan\u003e\u003c/span\u003e\u003cimg alt=\"Collapse icon\" loading=\"lazy\" width=\"15\" height=\"15\" decoding=\"async\" data-nimg=\"1\" srcset=\"https://www.inc.com/_next/image?url=%2F_public%2Fcollapse-icon_2x.webp\u0026amp;w=16\u0026amp;q=75 1x, https://www.inc.com/_next/image?url=%2F_public%2Fcollapse-icon_2x.webp\u0026amp;w=32\u0026amp;q=75 2x\" src=\"https://www.inc.com/_next/image?url=%2F_public%2Fcollapse-icon_2x.webp\u0026amp;w=32\u0026amp;q=75\"/\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-testid=\"content-chunk\"\u003e\u003cp\u003eBased on a company \u003ca href=\"https://www.linkedin.com/pulse/koru-pharma-driving-innovation-global-aesthetics-embarking-fiptc/\" target=\"_blank\" rel=\"noreferrer noopener\"\u003eannouncement, \u003c/a\u003eKoru recently attracted pre-IPO investment from KB Investment, a South Korean institutional fund—signaling renewed interest in aesthetic science as a long-term healthtech category, not just a cosmetic one. With its portfolio of non-invasive anti-aging products distributed in over 100 countries, the company may serve as a case study in how to scale precision biotech globally without sacrificing efficiency or focus. \u003c/p\u003e\u003cp\u003eWhat stands out is not just what they’ve built, but how they’ve built it. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eA sustainability approach\u003c/strong\u003e \u003c/p\u003e\u003c/div\u003e\u003cdiv data-testid=\"content-chunk\"\u003e\u003cp\u003eThere’s a kind of sustainability embedded in this approach—in environmental terms, but also in business architecture. A sustainable company is one that understands its systems, resists overextension, and scales without burning out its people or its purpose. These aren’t qualities we often associate with unicorn culture—but maybe we should. \u003c/p\u003e\u003cp\u003eHere in the U.S., many startups are facing hard questions about how they’ve grown: bloated valuations, misaligned incentives, shallow product pipelines. The contrast with Korea’s quiet biotech ascent is worth noting. In sectors like regenerative medicine and aesthetic health, it’s not just about disruption—it’s about durability. \u003c/p\u003e\u003cp\u003eEntrepreneurs looking beyond traditional playbooks might find inspiration not in what’s loudest, but what’s lasted. And in the case of South Korea’s aesthetic biotech ecosystem, the signals are clear: strong fundamentals still matter, cross-cultural fluency is a competitive advantage, and innovation that respects both biology and business often wins in the end. \u003c/p\u003e\u003c/div\u003e\u003cp\u003eAs one investor put it in a recent biotech summit, \u003cem\u003e“The most interesting companies right now are the ones that don’t need to tell you how interesting they are.”\u003c/em\u003e That feels especially true in a moment where the quiet builders may, in the long run, have the most to say. \u003c/p\u003e\u003cdiv\u003e\u003cp\u003e\u003cem\u003eThe super early-rate deadline for the 2025 \u003ca href=\"https://incpowerpartners.secure-platform.com/a\"\u003eInc. Power Partner Awards\u003c/a\u003e is Friday, May 30, at 11:59 p.m. PT. \u003ca href=\"https://incpowerpartners.secure-platform.com/a\"\u003eApply now\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "4 min read",
  "publishedTime": "2025-05-29T21:12:19Z",
  "modifiedTime": "2025-05-29T21:12:22Z"
}
